http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-184715-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7abafe538886c9684c458dec4d2d4725
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K50-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L2-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14
filingDate 2008-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_930b38503745adf1855c7f841f6f6dcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08529edc61c5994f1bbc8a0ebcf996d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6438a31768cc79139ba0ce2e503b1b15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eabb744d55c83656c2d1c08266a7f6d
publicationDate 2012-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SG-184715-A1
titleOfInvention Anti-fatigue agents and oral compositions containing andrographolide as active ingredient
abstract ANTI-FATIGUE AGENTS AND ORAL COMPOSITIONS CONTAINING ANDROGRAPHOLIDE AS ACTIVE INGREDIENTDisclosed is a composition which is safe for a human body and an animal, can be ingested continuously on a daily basis, has an anti-fatigue activity, and is effective for the prevention or treatment of a disease or condition associated with fatigue. Specifically disclosed is an anti-fatigue agent comprising andrographolide optionally together with an a-lipoic acid as an active ingredient(s). Also disclosed is a novel oral composition comprising andrographolide and an a-lipoic acid. The anti-fatigue agent and the oral composition are useful for the prevention or treatment of chronic fatigue syndrome, overfatigue, physical fatigue, mental fatigue and organ fatigue.No suitable figure
priorityDate 2007-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419560248
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426132826
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7067324
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5318517

Total number of triples: 35.